Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15)

Harada, Kaito; Doki, Noriko; Aoki, Jun; Mori, Jinichi; Machida, Shinichiro; Masuko, Masayoshi; Uchida, Naoyuki; Najima, Yuho; Fukuda, Takahiro; Kanamori, Heiwa; Ogawa, Hiroyasu; Ota, Shuichi; Ogawa, Kaoru; Takahashi, Satoshi; Kasai, Masanobu; Maeda, Akio; Nagafuji, Koji; Kawakita, Toshiro; Ichinohe, Tatsuo; Atsuta, Yoshiko

doi:10.3324/haematol.2017.179804

Cited by 5 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 2-year OS and DFS rates of AML patients with the translocation who underwent allogeneic HSCT after the first CR were 60.6% and 56.1%, respectively. These rates were higher than those observed in patients who underwent allogeneic HSCT after the second CR (OS, 37.3%; DFS, 25.0%) [ 12 ].…”

Section: Review Of Literature and Discussionmentioning

confidence: 84%

Acute Myelogenous Leukemia with the t(7;7)(p15;p22) Translocation, a Novel Simple Variant of t(7;11)(p15;p15) Translocation: First Description

Shibusawa

2021

Case Reports in Hematology

View full text Add to dashboard Cite

The t(7;11)(p15;p15) translocation is a recurrent genetic abnormality associated with acute myelogenous leukemia (AML). The translocation results in a fusion between the nucleoporin 98 and homeobox genes. We describe a case of AML with t(7; 7)(p15;p22) translocation, which is a novel simple variant of the t(7;11)(p15;p15) translocation. A 66-year-old woman presented with subcutaneous hemorrhage in both forearms. Laboratory test revealed hyperleukocytosis (white blood cell count: 97,800 cells/µL (blasts, 51.0%)), anemia (hemoglobin level: 7.6 g/dL), thrombocytopenia (platelet count: 6.5 × 104/μL), and hyperfibrinolysis (elevated d-dimer level: 12.4 µg/mL; fibrin/fibrinogen degradation products: 26.9 µg/mL). The patient was diagnosed with AML; the blast morphology was unclassifiable according to the French-American-British classification. Flow cytometry CD45 gating revealed that the blasts expressed CD34, CD13, CD33, and CD117. G-banding of tumor cells revealed the t(7;7)(p15;p22) translocation [20/20]. The patient underwent chemotherapy. At 48 days of admission, the patient died of multiple organ failure. The t(7;7)(p15;p22) translocation involved chromosome 7p15, indicating its association with the homeobox genes. To the best of our knowledge, this is the first report of a patient with AML with the t(7;7)(p15;p22) translocation, which is a simple novel variant of the t(7;11)(p15;p15) translocation.

show abstract

Section: Review Of Literature and Discussionmentioning

confidence: 84%

Acute Myelogenous Leukemia with the t(7;7)(p15;p22) Translocation, a Novel Simple Variant of t(7;11)(p15;p15) Translocation: First Description

Shibusawa

2021

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

“…In different studies, relapse was observed despite allo-HSCT [58,116]. According to a study, allo-HSCT in the first complete remission (CR1) is more effective than HSCT in the second complete remission (CR2) for AML patients with NUP98::HOXA9 fusion [153]. These studies indicate that allo-HSCT is partially effective for NUP98 rearranged AML patients.…”

Section: Therapeutic Strategies To Treat Nup98 Fusion Positive Aml Pa...mentioning

confidence: 99%

NUP98 Rearrangements in AML: Molecular Mechanisms and Clinical Implications

Mohanty

2023

Onco

View full text Add to dashboard Cite

NUP98 fusions constitute a small subgroup of AML patients and remain a high-risk AML subtype. There are approximately 30 types of NUP98 fusions identified in AML patients. These patients show resistance to currently available therapies and poor clinical outcomes. NUP98 fusions with different fusion partners have oncogenic transformation potential. This review describes how the NUP98 gene acquires oncogenic properties after rearrangement with multiple partners. In the mechanistic part, the formation of nuclear bodies and dysregulation of the HoxA/Meis1 pathway are highlighted. This review also discusses mutational signatures among NUP98 fusions and their significance in leukemogenesis. It also discusses the clinical implications of NUP98 fusions and their associated mutations in AML patients. Furthermore, it highlights therapeutic vulnerabilities in these leukemias that can be exploited as therapeutic strategies. Lastly, this review discusses the gaps in our knowledge regarding NUP98 fusions in AML, as well as future research opportunities.

show abstract

“…Additionally, several studies have evaluated the outcomes of allogeneic HCT in patients with specific cytogenetic abnormalities including trisomy 8 11 , t (7;11) (p15; p15) 12 , and abnormalities in the short arm of chromosome 17 13 . These studies provided detailed information regarding factors affecting post-transplant outcomes for each cytogenetically distinct group and highlighted the importance of conducting allogeneic HCT during CR1 in these patients.…”

Section: Cytogeneticsmentioning

confidence: 99%

Hematopoietic cell transplantation in adults with acute myeloid leukemia: A review of the results from various nationwide registry studies in Japan

Arai

Konuma

Yanada

2021

BCT

View full text Add to dashboard Cite

Hematopoietic cell transplantation (HCT) is an integral part of the treatment of acute myeloid leukemia (AML) . Although AML is the most common indication for allogeneic HCT, the relatively small number of patients and the highly complex nature of the procedure often render prospective studies on HCT unfeasible. Observational studies using registry data serve as important sources of information under such circumstances. Thus, the Japanese Society of Hematopoietic Cell Transplantation (JSHCT) has been conducting a nationwide survey of HCT since 1993, and this registration program now covers ＞99% of transplantation centers in Japan. A constant increase in the number of HCT procedures has been noted with recent annual registrations recording more than ＞1,000 new AML patients undergoing allogeneic or autologous HCT. Since its establishment in 2010, the Adult AML Working Group within the JSHCT has been using this registry data to complete several studies focusing on various aspects of HCT in adults with AML, with particular attention paid to patient-, disease-, and transplantation-related factors. This article comprehensively reviews the results obtained from these studies and discusses the strengths and limitations of these kinds of registry-based studies.

show abstract

Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15)

Cited by 5 publications

References 13 publications

Acute Myelogenous Leukemia with the t(7;7)(p15;p22) Translocation, a Novel Simple Variant of t(7;11)(p15;p15) Translocation: First Description

Acute Myelogenous Leukemia with the t(7;7)(p15;p22) Translocation, a Novel Simple Variant of t(7;11)(p15;p15) Translocation: First Description

NUP98 Rearrangements in AML: Molecular Mechanisms and Clinical Implications

Hematopoietic cell transplantation in adults with acute myeloid leukemia: A review of the results from various nationwide registry studies in Japan

Contact Info

Product

Resources

About